

***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on Friday 6<sup>th</sup> October 2023. I am pleased to confirm the following.

**Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)- 3**
- **Amivantamab- 0**
- **Atezolizumab Monotherapy-0**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel-0**
- **Dabrafenib + Trametinib-0**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin-0**
- **Durvalumab-1**
- **Gemcitabine- 4**
- **Nitedanib + Docetaxel- 4**
- **Nivolumab- 0**
- **Osimertinib- 11**
- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)-2**
- **Paclitaxel-0**
- **Pembrolizumab Monotherapy -15**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)- 1**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)-5**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin)- 1**
- **RET Inhibitors (Pralsetinib, Selpercatinib)-0**
- **Sotorasib-0**
- **Tepotinib-0**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin-2**
- **Other active systemic anti-cancer therapy-0**
- **Palliative care only- no access to this information**

**Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?**

**2**

**Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.**

MKUH currently has no NSCLC clinical trials open or in follow-up.

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.